0102030405
Sacubitril CAS No. 149709-62-6 Pharmaceutical Raw Material
02
introduce
introduce
Sacubitril is a potent prodrug and core pharmaceutical API, acting as a selective neprilysin inhibitor. It is combined with valsartan (1:1 molar ratio) to form LCZ696, an innovative therapy for heart failure.
Our products comply with strict international standards to ensure high purity, stable efficacy, and reliable supply for clinical use and pharmaceutical formulation.
02
Physical and chemical properties
Sacubitril exhibits key physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Boiling Point: 656.9±55.0 °C
- Density: 1.2±0.1 g/cm³
- Storage Temperature: Sealed in dry condition, stored in freezer at -20 °C
- Solubility: Soluble in DMSO (≥41.1 mg/mL), water (≥21.45 mg/mL with ultrasonic) and ethanol (≥26.85 mg/mL with ultrasonic)
- Boiling Point: 656.9±55.0 °C
- Density: 1.2±0.1 g/cm³
- Storage Temperature: Sealed in dry condition, stored in freezer at -20 °C
- Solubility: Soluble in DMSO (≥41.1 mg/mL), water (≥21.45 mg/mL with ultrasonic) and ethanol (≥26.85 mg/mL with ultrasonic)
1. More Comprehensive Mechanism of Action
When combined with valsartan at a 1:1 molar ratio to form a compound preparation, it has dual effects of neprilysin inhibition and angiotensin II AT1 receptor antagonism. It can regulate cardiovascular function through multiple pathways, and its antihypertensive efficacy is superior to that of standard antihypertensive drugs.
When combined with valsartan at a 1:1 molar ratio to form a compound preparation, it has dual effects of neprilysin inhibition and angiotensin II AT1 receptor antagonism. It can regulate cardiovascular function through multiple pathways, and its antihypertensive efficacy is superior to that of standard antihypertensive drugs.
2. Outstanding Clinical Efficacy and Safety
In phase III clinical trials, its compound preparation showed better efficacy and safety than enalapril, the clinical standard anti-heart failure drug. It can more effectively improve the condition of patients with heart failure, providing a better option for heart failure treatment.
In phase III clinical trials, its compound preparation showed better efficacy and safety than enalapril, the clinical standard anti-heart failure drug. It can more effectively improve the condition of patients with heart failure, providing a better option for heart failure treatment.
3. Stable Active Transformation
Sacubitril itself is a prodrug that can be enzymatically hydrolyzed into the active form LBQ657 in vivo to exert precise efficacy. Compared with drugs directly using active ingredients, its action process in vivo is more stable and controllable.
1. Core Application Scenario
Combined with valsartan to form a compound preparation, it is mainly used for the treatment of heart failure and is a new type of therapeutic drug for heart failure.
2. Auxiliary Antihypertensive Effect It has antihypertensive effects and can be used as an antihypertensive drug to help regulate blood pressure levels.
3. Biomedical Research Tool compound for studying neprilysin-related pathways, heart failure pathogenesis, and development of novel cardiovascular therapeutics.
2. Auxiliary Antihypertensive Effect It has antihypertensive effects and can be used as an antihypertensive drug to help regulate blood pressure levels.
3. Biomedical Research Tool compound for studying neprilysin-related pathways, heart failure pathogenesis, and development of novel cardiovascular therapeutics.
We implement strict full-process quality control, with each batch of Sacubitril undergoing rigorous testing of key indicators including purity, solubility, optical activity, stability, and impurity content to meet standards.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and production needs.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address clinical and production needs.
As a key component of the first-in-class ARNI therapy, Sacubitril has transformed heart failure treatment by leveraging synergistic dual mechanisms. With its potent efficacy, proven clinical benefits, exceptional quality, and reliable supply capacity, we are committed to providing high-quality Sacubitril API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Sacubitril to meet your needs in pharmaceutical formulation, cardiovascular research, and clinical treatment. Contact us for more product details and cooperation support.
Choose our Sacubitril to meet your needs in pharmaceutical formulation, cardiovascular research, and clinical treatment. Contact us for more product details and cooperation support.